![Editas Medicine, Inc. logo](/logos/EDIT.webp)
Editas Medicine, Inc.
NASDAQ:EDIT
Overview | Financials
Company Name | Editas Medicine, Inc. |
Symbol | EDIT |
Currency | USD |
Price | 3.59 |
Market Cap | 296,090,276 |
Dividend Yield | 0% |
52-week-range | 3.4 - 11.69 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gilmore O'Neill |
Website | https://www.editasmedicine.com |
An error occurred while fetching data.
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD